Compare General Dynamics Corporation (GD) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs GSK plc — how do they compare? General Dynamics Corporation trades at $365.8 (market cap $98.88B), while GSK plc trades at $52.85 (market cap $101.34B). The key difference: General Dynamics Corporation and GSK plc are close in size by market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GD | GSK | |
|---|---|---|
Market Cap | $98.88B | $101.34B |
Sector | Industrials | Health |
52-Week High | $376.88 | $61.18 |
52-Week Low | $297.05 | $36.20 |
Enterprise Value | $105.06B | $121.95B |
Dividend Yield | 1.74% | 3.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $366.40, down 0.84% on the day, with strong technical momentum indicated by bullish moving averages and oscillators. The company demonstrates solid fundamentals with Q1 2026 EPS beating expectations at $4.10 versus $3.67, continuing a trend of earnings outperformance. Revenue growth has been consistent, reaching $52.55 billion in 2025 with an 8.07% net income margin. Analyst sentiment remains positive with a $395.83 consensus price target and 53% buy ratings.
The outlook for GD is favorable given strong defense spending tailwinds and a growing $130.8 billion backlog, particularly in marine systems. However, risks include execution challenges on large contracts and potential defense budget volatility. The stock's current valuation at 23x P/E appears reasonable relative to earnings growth prospects, positioning it as a core defense holding for long-term investors.
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
